Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9906286 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL9906297 | 0.80 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL2990488 | 0.80 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL9906283 | 0.79 | CHRNB2 (0.66) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL2986908 | 0.79 | CHRNB2 (0.66) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL9906291 | 0.78 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL2984864 | 0.78 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL18039987 | 0.70 | MAPT (0.38) | KMT2A | |
| SCHEMBL32668922 | 0.70 | CYP3A4 (0.35) | — | |
| SCHEMBL32668746 | 0.70 | CYP3A4 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139857-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | Targacept Inc. (US) | 2010-01-06 | — | — | EP | claimed |
| WO-2008121686-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | TARGACEPT, INC. (US) | 2008-10-09 | — | — | WO | claimed |
| US-8198296-B2 | Sub-type selective azabicycloalkane derivatives | TARGACEPT, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100173968-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | TARGACEPT, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| EP-2139857-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | Targacept Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008121686-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | TARGACEPT, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173968-A1 | SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES | CHRNB2, CHRNB4, CHRNA4 | CHRNB2 1/4885CHRNA4 3/4885CHRNA7 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.